Quanta Dialysis Technologies
Quanta Receives FDA 510(k) Clearance for the SC+ Hemodialysis System Setting the Stage for US Market Launch
Quanta Receives FDA 510(k) Clearance for the SC+ Hemodialysis System Setting the Stage for US Market Launch
Quanta Receives FDA 510(k) Clearance for
the SC+ Hemodialysis System
Setting the Stage for US Market Launch
Alcester, Warwickshire, UK, 8 January 2021: Quanta Dialysis Technologies Ltd (“Quanta” or “the Company”), a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces it has received 510(k) clearance from the US Food and Drug Administration (“FDA”) to market its small and simple, high performance hemodialysis system SC+. This critical milestone enables Quanta to bring to the American market its portable device that can provide a dialysis dose equivalent to today s standard of care, but in a compact, easy-to-use format suitable for a range of c
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
Achilles TherapeuticsJanuary 8, 2021 GMT
Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
London, UK 7 January 2021 – Achilles Therapeutics (“Achilles” or the “Company”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours, today announced the appointment of Arjan Roozen as VP, Site Head and General Manager, with responsibility for scaling up Achilles’ manufacturing operations to supply cell therapy products for late-stage clinical studies and commercial supply. Arjan brings over 25 years of experience in the field of advanced therapies and Good Manufacturing Practices (GMP) operations, from early phase to commercial manufacture.
Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Orally-administered,
non-absorbable engineered carbon, Carbalive
, was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis
Safety of novel dual filtration system, Dialive
, confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group
London, UK, 7 January 2021 - Yaqrit, a clinical stage life sciences company focused on developing potentially innovative treatments for patients with advanced liver disease in areas of high unmet medical need, today announces preliminary results from its randomised controlled clinical trials for two potential therapies from its pipeline of product candidates designed to address each stage of liver disease, from diagnosis of decompensated c
Yaqrit Discovery Ltd
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Orally-administered,
non-absorbable engineered carbon, Carbalive
™, was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis
Safety of novel dual filtration system, Dialive
™, confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group
The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive
Safety of novel liver dialysis device confirmed
Liver failure patients in ICU treated with Dialive more likely to see organ failure resolved, and more quickly (p=0.03)
Significant improvements in mechanistic biomarkers of how Dialive improves organ function
7
th January 2021 - The
ALIVER Consortiumis pleased to announce positive data from the randomised controlled clinical trial of Dialive in adult patients with liver failure. The study found that twice as many patients with a history indicative of alcohol-related cirrhosis suffering from multiorgan failure, a condition referred to as acute-on-chronic liver failure (ACLF), recovered to having no organ failure when treated with the Dialive device compared to the control group.